RNA干扰药物用于疾病治疗的安全性问题

RNA干扰(RNA interference,RNAi)是指由双链RNA介导的序列特异的转录后基因沉默.RNAi技术因其特异性.高效性而备受青睐,在疾病治疗方面表现出广阔的应用前景.然而,近年来的研究发现,基于RNAi技术开发的药物存在安全性问题,主要包括引起免疫反应,产生脱靶效应、以及存在竞争微RNA通路等.这些问题的突破将使RNAi技术获得更加广泛的应用.     

RNA干扰药物用于疾病治疗的安全性问题

RNA干扰（RNA interference,RNAi）是指由双链RNA介导的序列特异的转录后基因沉默。RNAi技术因其特异性、高效性而备受青睐,在疾病治疗方面表现出广阔的应用前景。然而,近年来的研究发现,基于RNAi技术开发的药物存在安全性问题,主要包括引起免疫反应、产生脱靶效应、以及存在竞争微RNA通路等。这些问题的突破将使RNAi技术获得更加广泛的应用。     

siRNA脱靶效应类型与规避策略

小干扰RNAs(small interfere RNAs,siRNAs)能够特异性沉默靶基因,现已广泛应用于阐明基因功能,鉴定药物靶点,开发比目前更有效的治疗药物。然而siRNA脱靶效应(off-target effects,OTEs)导致基因沉默实验中表型效应解释复杂化,引起siRNA治疗毒副作用。与siRNA有关的脱靶效应有microRNA样脱靶效应、免疫刺激、RNAi元件饱和三种类型。综述了siRNA脱靶效应类型及减轻脱靶效应的方法,以增强该技术的实用性。     

植物介导的害虫RNA干扰

摘要: 应用植物介导的昆虫RNAi进行害虫防治近10年来受到了广泛的关注,其作用机理包括两个阶段,首先是害虫靶标基因dsRNA在植物体内的表达、运输和贮存,然后是害虫取食该植物后,dsRNA特异性抑制害虫体内靶标基因的表达。目前,植物介导的昆虫RNAi主要针对鳞翅目、鞘翅目和同翅目害虫,可以引起害虫生长发育的异常,导致死亡/繁殖力下降,甚至影响到其子代的生长。影响植物介导昆虫RNAi效率的因素主要包括害虫靶标基因的选择、dsRNA靶定位点及长度、植物表达dsRNA载体的结构和转基因植物的遗传转化方式等。植物介导昆虫RNAi防治害虫的策略也面临着潜在的安全性问题,如转基因植物安全性和RNAi潜在脱靶性等。随着植物介导昆虫RNAi技术的成熟,该方法有望成为害虫防治的新策略。     

siRNA脱靶效应研究进展

RNA干扰过程中,siRNA和mRNA特异结合能够使得靶基因沉默。但研究证实,siRNA可能与非靶基因结合而导致非靶基因沉默,这种现象称为siRNA脱靶效应。多种真核生物中的RNA干扰实验证实了脱靶效应的存在。对脱靶机制的研究发现脱靶可能与模体匹配、结构和长dsRNA等有关,很多新方法被提出来预测脱靶概率和检测脱靶基因。通过利用siRNApool、化学修饰和生物信息学方法能够尽可能地降低脱靶效应,提高RNAi实验的质量。对脱靶效应方面的研究进行了总结论述。     

RNAi生物技术作物环境风险评估研究进展

RNA干涉(RNAi)在昆虫遗传和功能基因研究方面广泛应用。近年来,RNAi被认为是具有应用潜力的害虫防治新方法。具有良好抗虫性状的RNAi生物技术作物已研究成功,预示其商业化应用成为可能。因此,有关RNAi作物的生态风险是商业化应用前人们所关心的问题。要建立RNAi生物技术作物环境安全评价准则,监管者、受益各方及风险评估者必须要了解RNAi理论及其在生物技术领域的应用。科学分析并准确提出RNAi作物的生态风险问题,如非期望的基因沉默、靶外结合或脱靶效应、靶标害虫的抗性、小干涉RNA(si RNA)的环境持久性和不确定性等,并通过研究获得科学数据,将为政府依法监管提供依据。RNAi生物技术作物的环境风险评估主要包括功能基因及其表达特征(如ds RNA序列、长度、表达浓度及沉默效果的持续性等)、杀虫谱及对非靶标生物的影响、环境中的残留问题、功能性状的持续稳定性等。现行的生物技术作物环境风险评估方法和内容需要进一步修改完善,以适应今后RNAi生物技术作物的发展和应用。     

RNAi及其在肿瘤研究中的应用

RNA干扰(RNA interference,RNAi)是指在生物体细胞内,外源性或内源性的双链RNA(double-stranded RNA,dsRNA)引起与其同源mRNA特异性的降解,因而抑制其相应的基因表达过程.由于它能够高度特异性、高效性地抑制基因的表达,因此在研究基因功能及表达调控、信号传导通路、药物靶点的鉴定和基因药物开发等方面具有良好的应用前景.主要介绍RNAi可能的分子机制、分子生物学特性、产生方法及其在肿瘤研究中的应用.     

RNA干扰在抗乙肝治疗中的应用及其研究进展

据世界卫生组织(WHO)报道,全世界约有20亿人曾感染过乙型肝炎病毒(HBV),其中3.5亿人为慢性HBV感染者.我国现有1.3亿乙肝病毒携带者和3 000多万乙肝患者,其中约有20%～40%的患者经过多年慢性炎症的反复发作可发展为肝硬化和肝癌.然而,至今人们仍没有找到一种能够彻底治愈慢性乙肝的特效药物.自从RNA干扰(RNA interference,RNAi)技术建立以来,人们致力于将其应用于抗病毒药物的研究与开发.研究结果表明,RNAi可有效地抑制乙肝病毒的复制,但靶向目的基因的不同RNA干扰片段所沉默的效率不同.关于将RNAi抗病毒药物应用于人体治疗的安全性和有效性还有待进一步研究,RNAi发生"脱靶"的现象是临床应用的难点之一.     

RNA干扰在疾病治疗上的应用

RNA干扰(RNA interference,RNAi)是一种双链RNA分子在mRNA水平上引发的特异性基因沉默现象。RNAi在基因治疗方面表现出了光明的前景,已成功地应用于多种疾病的临床治疗。本文主要介绍了RNAi在疾病治疗上的应用及研究进展。     

RNAi技术在蜂学研究中的应用

RNA干扰(RNA interference,RNAi)是指外源或内源的双链RNA(dsRNA)特异性引起基因表达沉默的现象,特异性和高效性是RNAi技术的特点。本文主要从调控目标基因的表达、级型分化的分子基础、防治蜜蜂病毒病3个方面概述了RNAi技术在蜂学研究中的应用进展情况,并展望RNAi技术在蜜蜂功能基因组研究领域的应用前景。     

Validation of RNAi silencing specificity using synthetic genes: salicylic acid-binding protein 2 is required for innate immunity in plants

RNA interference (RNAi) is widely used to specifically silence the expression of any gene to study its function and to identify and validate therapeutic targets. Despite the popularity of this technology, recent studies have shown that RNAi may also silence non-targeted genes. Here we demonstrate the utility of a quick, efficient and robust approach to directly validate the specificity of RNAi as an alternative to indirect validation of RNAi through gene expression profiling. Our approach involves reversing (complementing) the RNAi-induced phenotype by introducing a synthetic version of the target gene that is designed to escape silencing. This synthetic gene complementation approach can also be used for mutational analysis of the target gene, or to provide a functional version of a defective protein after silencing the defective gene by RNAi. Using this approach we demonstrate that the loss of systemic acquired resistance, a form of innate immunity in plants, is indeed due to the silencing of salicylic acid-binding protein 2 rather than to off-target effects.     

CRISPR/Cas9的应用及脱靶效应研究进展

CRISPR/Cas9基因编辑技术在生命科学领域掀起了一场全新的技术革命,该技术可以对基因组特定位点进行靶向编辑,包括缺失、插入、修复等。CRISPR/Cas9比锌指核酸酶 (ZFNs)和转录激活因子样效应物核酸酶(TALENs)技术更易于操作,而且更高效。CRISPR/Cas9系统中的向导RNA(Single guide RNA, sgRNA)是一段与目标DNA片段匹配的RNA序列,指导Cas9蛋白对基因组进行识别。研究发现,设计的sgRNA会与非靶点DNA序列错配,引入非预期的基因突变,即脱靶效应(Off-target effects)。脱靶效应严重制约了CRISPR/Cas9基因编辑技术的广泛应用。为了避免脱靶效应,研究者对影响脱靶效应的因素进行了系统研究并提出了许多降低脱靶效应的方法。文章总结了CRISPR/Cas9系统的应用及脱靶效应研究进展,以期为相关领域的工作提供参考。     

VEGF inhibitor (Iressa) arrests histone deacetylase expression: single-cell cotransfection imaging cytometry for multi-target-multi-drug analysis

Multi-target-multi-drug approaches are needed to accelerate the process of drug discovery screening and to design efficient therapeutic strategies against diseases that involve alterations in multiple cellular targets. Herein we report single-cell cotransfection imaging cytometry to quantitatively screen drug-induced off-target effects. Vascular endothelial growth factor (VEGF) and histone deacetylase (HDAC) genes amplified from the genomic DNA were cloned in fluorescently tagged gene constructs (RFP-HDAC/YFP-VEGF). These gene constructs were cotransfected in HEK-293 cells to explore the possibility of off-target effects of 4-phenylbutyrate and Iressa on the expression of VEGF and HDAC through single-cell imaging cytometry. Iressa (10 μM) treatment at the time of cotransfection or 48 h after cotransfection of RFP-HDAC/YFP-VEGF plasmids in HEK-293 cells resulted in off-target effects on HDAC expression. These results suggest possible applications of Iressa in the treatment of diseases in which expression of both HDAC and VEGF should be inhibited. 4-Phenylbutyrate (2.0 mM) did not show any off-target effects on VEGF expression. The developed quantitative multicolor live single-cell cotransfection imaging can be employed to select better drug combinations for faster screening and greater accuracy in multi-target-multi-drug analysis by increasing the on-target/desired off-target effects and eliminating the undesirable off-target effects.     

Cas9 Cuts and Consequences; Detecting,Predicting, and Mitigating CRISPR/Cas9 On- and Off-Target Damage

Large deletions and genomic re-arrangements are increasingly recognized as common products of double-strand break repair at Clustered Regularly Interspaced, Short Palindromic Repeats - CRISPR associated protein 9 (CRISPR/Cas9) on-target sites. Together with well-known off-target editing products from Cas9 target misrecognition, these are important limitations, that need to be addressed. Rigorous assessment of Cas9-editing is necessary to ensure validity of observed phenotypes in Cas9-edited cell-lines and model organisms. Here the mechanisms of Cas9 specificity, and strategies to assess and mitigate unwanted effects of Cas9 editing are reviewed; covering guide-RNA design, RNA modifications, Cas9 modifications, control of Cas9 activity; computational prediction for off-targets, and experimental methods for detecting Cas9 cleavage. Although recognition of the prevalence of on- and off-target effects of Cas9 editing has increased in recent years, broader uptake across the gene editing community will be important in determining the specificity of Cas9 across diverse applications and organisms.     

In silico abstraction of zinc finger nuclease cleavage profiles reveals an expanded landscape of off-target sites

Gene-editing nucleases enable targeted modification of DNA sequences in living cells, thereby facilitating efficient knockout and precise editing of endogenous loci. Engineered nucleases also have the potential to introduce mutations at off-target sites of action. Such unintended alterations can confound interpretation of experiments and can have implications for development of therapeutic applications. Recently, two improved methods for identifying the off-target effects of zinc finger nucleases (ZFNs) were described–one using an in vitro cleavage site selection method and the other exploiting the insertion of integration-defective lentiviruses into nuclease-induced double-stranded DNA breaks. However, application of these two methods to a ZFN pair targeted to the human CCR5 gene led to identification of largely non-overlapping off-target sites, raising the possibility that additional off-target sites might exist. Here, we show that in silico abstraction of ZFN cleavage profiles obtained from in vitro cleavage site selections can greatly enhance the ability to identify potential off-target sites in human cells. Our improved method should enable more comprehensive profiling of ZFN specificities.     

CRISPR/Cas9系统中sgRNA设计与脱靶效应评估

基于CRISPR/Cas9系统介导的第三代基因组编辑技术,已成功应用于动物、植物和微生物等诸多物种的基因组改造。如何提高CRISPR/Cas9技术的基因组编辑效率和最大限度降低脱靶风险一直是本领域的研究热点,而使用高效且特异的sgRNA(Small guide RNA)是基因组改造成功的关键性因素之一。目前,已有多款针对CRISPR/Cas9技术的sgRNA设计和/或脱靶效应评估软件,但不同的软件各有优缺点。本文重点对16款sgRNA 设计和脱靶效应评估在线和单机版软件的特点进行了阐述,通过制定38项评估指标对不同软件进行了比较分析,最后对11种用于检测基因组编辑效率和脱靶的实验方法,以及如何筛选高效且特异的sgRNA进行了归纳总结。